Key Takeaways
- Commercialization should begin as strategic thinking well before commercial infrastructure is built.
- First-launch biotechnology companies need longer preparation because commercial capabilities must often be created from zero.
- Market access, evidence, organization and commercial strategy should develop together.
- Early commercial planning improves both launch readiness and strategic optionality.
One of the questions emerging biotechnology leaders frequently confront is deceptively simple:
When should we begin preparing for commercialization?
The conventional answer is often tied to a clinical or regulatory milestone—Phase III, NDA submission, or FDA approval.
In my experience, that framing misses the larger issue.
Commercialization is not an event that begins when a commercial organization is hired. It is the culmination of decisions made throughout development.
The better question is therefore:
Which commercial decisions must be made now because waiting will reduce our options later?
Commercial Planning by Development Stage
Preclinical and Early Development
Commercial planning at this stage should not mean building a commercial organization. The objective is to begin testing the assumptions that may later determine whether an asset represents a viable commercial opportunity.
Leadership should begin asking basic but consequential questions. Who is the patient? How are patients identified and diagnosed? Which physicians manage the disease? How concentrated is specialist care? What does current treatment look like? Where could a new therapy create meaningful value?
Answers will remain preliminary, but identifying uncertainty early gives the company time to generate better evidence.
Phase I
Phase I remains primarily a clinical milestone, but commercial questions should begin informing strategic discussion.
The company should develop an initial commercial hypothesis covering the patient population, treatment pathway, competitive environment, potential differentiation, specialist landscape and likely access complexity.
The purpose is not forecasting precision. It is identifying assumptions that could materially affect development, indication sequencing, evidence generation or future investment.
Phase II
Phase II is often where commercial planning should become more disciplined.
Leadership should increasingly understand the diagnosed and addressable population, patient journey, referral pathways, physician segmentation, Centers of Excellence, competitive development landscape, early payer considerations and evidence needs.
This is also the period in which companies should begin examining the likely commercial model.
Will the therapy require a concentrated specialist field organization? Significant patient services? Specialty pharmacy infrastructure? Complex reimbursement support? Extensive physician education?
These questions can influence decisions long before launch infrastructure is required.
Phase III
By Phase III, commercial planning should increasingly convert learning into decisions.
The organization should be refining product positioning, launch assumptions, access strategy, organizational design, leadership requirements, capability development, commercial operations and launch governance.
Critical evidence gaps should be visible.
Leadership should understand what must be built internally, what can be outsourced and when each capability must become operational.
Pre-Launch
The final pre-launch period should focus increasingly on readiness and execution rather than discovering fundamental market assumptions for the first time.
Market understanding, access planning, organizational capability, operational readiness, Medical Affairs coordination and launch governance should converge into one integrated commercial plan.
For a first-launch biotechnology company, this period also requires the organization itself to transform from an R&D-centered company into an enterprise capable of commercial execution.
| Development Stage | Primary Commercial Objective |
|---|---|
| Preclinical | Understand the market hypothesis and major uncertainties |
| Phase I | Develop an early commercial hypothesis |
| Phase II | Validate market, patient, physician and access assumptions |
| Phase III | Convert learning into organizational and launch decisions |
| Pre-Launch | Execute an integrated commercialization roadmap |
Related resources: biotech commercial strategy, commercial readiness framework, launch readiness assessment, first commercial launch and commercial market access strategy.
Preparing for Commercialization?
Commercial decisions begin before the commercial organization exists. PharmaKonsult works with biotechnology CEOs, boards and leadership teams to evaluate the decisions that shape commercial readiness, organizational capability and launch strategy.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
